Royalty Pharma PLC $RPRX Shares Purchased by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 16.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,827 shares of the biopharmaceutical company’s stock after buying an additional 1,627 shares during the quarter. Integrated Quantitative Investments LLC’s holdings in Royalty Pharma were worth $426,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Nordea Investment Management AB boosted its stake in shares of Royalty Pharma by 603.9% during the second quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after buying an additional 562,799 shares during the period. Cookson Peirce & Co. Inc. raised its stake in Royalty Pharma by 55.1% during the 2nd quarter. Cookson Peirce & Co. Inc. now owns 34,263 shares of the biopharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 12,171 shares during the last quarter. Koss Olinger Consulting LLC lifted its position in Royalty Pharma by 201.5% during the 1st quarter. Koss Olinger Consulting LLC now owns 31,756 shares of the biopharmaceutical company’s stock worth $989,000 after acquiring an additional 21,225 shares during the period. Wealthedge Investment Advisors LLC purchased a new position in shares of Royalty Pharma in the 1st quarter valued at approximately $389,000. Finally, Jupiter Asset Management Ltd. raised its stake in shares of Royalty Pharma by 126.5% during the second quarter. Jupiter Asset Management Ltd. now owns 2,470,706 shares of the biopharmaceutical company’s stock worth $89,020,000 after purchasing an additional 1,380,115 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Morgan Stanley decreased their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Citigroup raised their price target on Royalty Pharma from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, July 22nd. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and a consensus price target of $46.00.

Royalty Pharma Stock Down 1.4%

RPRX opened at $39.16 on Monday. The firm has a market cap of $22.60 billion, a P/E ratio of 29.67, a PEG ratio of 2.06 and a beta of 0.56. The business’s fifty day simple moving average is $36.78 and its 200 day simple moving average is $35.71. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $41.24. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million for the quarter, compared to analyst estimates of $765.01 million. As a group, equities research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 annualized dividend and a dividend yield of 2.2%. Royalty Pharma’s dividend payout ratio is presently 66.67%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.